Search Results for "drug"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for drug. Results 1841 to 1850 of 2586 total matches.

Colon Cleansing

   
The Medical Letter on Drugs and Therapeutics • May 18, 2009  (Issue 1312)
The Medical Letter ® On Drugs and Therapeutics Published by The Medical Letter, Inc. • 1000 ...
Web sites and blogs are advising patients that periodic "cleansing" of the colon is necessary to rid the body of toxins.
Med Lett Drugs Ther. 2009 May 18;51(1312):39-40 |  Show IntroductionHide Introduction

In Brief: Prevention of Stroke in Patients with Atrial Fibrillation

   
The Medical Letter on Drugs and Therapeutics • Jun 01, 2009  (Issue 1313)
The Medical Letter ® On Drugs and Therapeutics Published by The Medical Letter, Inc. • 1000 ...
Atrial fibrillation increases the risk of stroke by a factor of 5. A randomized controlled trial (ACTIVE W) in 6706 patients with atrial fibrillation and one or more additional risk factors (≥75 years old; hypertension; previous stroke, transient ischemic attack or non- CNS embolus; left ventricular ejection fraction <45%; peripheral vascular disease; or 55-74 years old plus diabetes or coronary artery disease) found that a vitamin K antagonist such as warfarin (Coumadin, and others) was superior to clopidogrel (Plavix) plus aspirin in preventing vascular events, especially ischemic...
Med Lett Drugs Ther. 2009 Jun 1;51(1313):41 |  Show IntroductionHide Introduction

Vasopressors and Inotropes

   
The Medical Letter on Drugs and Therapeutics • Nov 14, 2011  (Issue 1377)
The Medical Letter® On Drugs and Therapeutics www.medicalletter.org Published by The Medical ...
The main purpose of vasopressors is to raise arterial blood pressure, while that of inotropes is to increase cardiac contractility. The choice of drugs is dictated by the clinical setting. Controlled trials comparing the efficacy and safety of these drugs are generally lacking.
Med Lett Drugs Ther. 2011 Nov 14;53(1377):90-2 |  Show IntroductionHide Introduction

Ciltacabtagene Autoleucel (Carvykti) for Multiple Myeloma (online only)

   
The Medical Letter on Drugs and Therapeutics • Nov 14, 2022  (Issue 1663)
of therapy, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal ...
The FDA has approved ciltacabtagene autoleucel (Carvykti – Janssen), a B-cell maturation antigen (BCMA)-directed genetically-modified cellular product, for treatment of relapsed or refractory multiple myeloma in adults who received ≥4 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody. Carvykti is an individualized cellular product prepared from the patient's own T cells, which are genetically modified to express chimeric antigen receptors (CAR) and then infused back into the patient. Idecabtagene...
Med Lett Drugs Ther. 2022 Nov 14;64(1663):e188-9 |  Show IntroductionHide Introduction

Cariprazine (Vraylar) for Schizophrenia and Bipolar I Disorder

   
The Medical Letter on Drugs and Therapeutics • Apr 25, 2016  (Issue 1493)
The Medical Letter® on Drugs and Therapeutics Volume 58 (Issue 1493) April 25, 2016 Take CME ...
The FDA has approved cariprazine (Vraylar – Actavis), an oral, once-daily, second-generation antipsychotic, for treatment of schizophrenia and for acute treatment of manic or mixed episodes associated with bipolar I disorder.
Med Lett Drugs Ther. 2016 Apr 25;58(1493):51-3 |  Show IntroductionHide Introduction

Cefmetazole Sodium (Zefazone)

   
The Medical Letter on Drugs and Therapeutics • Jul 13, 1990  (Issue 822)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
Cefmetazole sodium (Zefazone - Upjohn), a second-generation parenteral cephalosporin, was recently marketed in the USA for intravenous (IV) treatment of various infections caused by susceptible organisms. Like cefotetan (Cefotan), cefamandole (Mandol), cefoperazone (Cefobid), and moxalactam (Moxam), cefmetazole contains a methylthiotetrazole group that has been associated with prothrombin deficiency.
Med Lett Drugs Ther. 1990 Jul 13;32(822):65-6 |  Show IntroductionHide Introduction

Trimethoprim-Polymyxin B for Bacterial Conjunctivitis

   
The Medical Letter on Drugs and Therapeutics • Jul 27, 1990  (Issue 823)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
Bacterial infections of the conjunctivae are usually self-limited, but topical antimicrobial therapy can be helpful. A solution of trimethoprim sulfate 0.1% with polymyxin B sulfate 10,000 units/ml (Polytrim - Burroughs Wellcome, distributed by Allergan) was recently marketed in the USA for treatment of superficial ocular bacterial infections.
Med Lett Drugs Ther. 1990 Jul 27;32(823):71-2 |  Show IntroductionHide Introduction

Calcipotriene for Psoriasis

   
The Medical Letter on Drugs and Therapeutics • Aug 05, 1994  (Issue 928)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
Calcipotriene ointment 0.005% (calcipotriol; Dovonex - Westwood Squibb), a synthetic vitamin D 3 analog previously available in Europe and Canada, has now been approved by the US Food and Drug Administration (FDA) for treatment of moderate plaque psoriasis, the most common form of the disease.
Med Lett Drugs Ther. 1994 Aug 5;36(928):70-1 |  Show IntroductionHide Introduction

Thalidomide

   
The Medical Letter on Drugs and Therapeutics • Oct 23, 1998  (Issue 1038)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
Thalidomide (Thalomid - Celgene), a synthetic derivative of glutamic acid, has been approved by the FDA for use in treatment of leprosy. Thalidomide was marketed in Europe in 1957 as a sedative but withdrawn four years later after being associated with severe human teratogenicity. The drug has since been found to be effective for several different indications.
Med Lett Drugs Ther. 1998 Oct 23;40(1038):103-4 |  Show IntroductionHide Introduction

A New Conjugated Estrogen

   
The Medical Letter on Drugs and Therapeutics • Jul 30, 1999  (Issue 1058)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
A new synthetic conjugated estrogen product (Cenestin - Duramed) was recently approved by the US Food and Drug Administration for treatment of vasomotor symptoms due to estrogen deficiency.
Med Lett Drugs Ther. 1999 Jul 30;41(1058):67-70 |  Show IntroductionHide Introduction